You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 11, 2024

~ Buy the POTASSIUM PHOSPHATES (potassium phosphate, dibasic; potassium phosphate, monobasic) Drug Profile, 2024 PDF Report in the Report Store ~

POTASSIUM PHOSPHATES Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Potassium Phosphates patents expire, and when can generic versions of Potassium Phosphates launch?

Potassium Phosphates is a drug marketed by Am Regent, Amneal, Cmp Dev Llc, Fresenius Kabi Usa, and Somerset Theraps Llc. and is included in six NDAs. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in POTASSIUM PHOSPHATES is potassium phosphate, dibasic; potassium phosphate, monobasic. There are two hundred and forty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the potassium phosphate, dibasic; potassium phosphate, monobasic profile page.

DrugPatentWatch® Generic Entry Outlook for Potassium Phosphates

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for POTASSIUM PHOSPHATES?
  • What are the global sales for POTASSIUM PHOSPHATES?
  • What is Average Wholesale Price for POTASSIUM PHOSPHATES?
Summary for POTASSIUM PHOSPHATES
International Patents:1
US Patents:1
Applicants:5
NDAs:6
Finished Product Suppliers / Packagers: 5
Clinical Trials: 1
What excipients (inactive ingredients) are in POTASSIUM PHOSPHATES?POTASSIUM PHOSPHATES excipients list
DailyMed Link:POTASSIUM PHOSPHATES at DailyMed
Drug patent expirations by year for POTASSIUM PHOSPHATES
Recent Clinical Trials for POTASSIUM PHOSPHATES

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mahidol UniversityN/A

See all POTASSIUM PHOSPHATES clinical trials

Pharmacology for POTASSIUM PHOSPHATES

US Patents and Regulatory Information for POTASSIUM PHOSPHATES

POTASSIUM PHOSPHATES is protected by one US patents and two FDA Regulatory Exclusivities.

Patents protecting POTASSIUM PHOSPHATES

Potassium phosphates composition for injection
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

FDA Regulatory Exclusivity protecting POTASSIUM PHOSPHATES

COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷  Sign Up

COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Am Regent POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 216274-001 Oct 2, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cmp Dev Llc POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 212121-001 Sep 19, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Amneal POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 216344-001 Oct 10, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Somerset Theraps Llc POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 217726-002 Jul 11, 2024 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 212832-001 Nov 26, 2019 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for POTASSIUM PHOSPHATES

See the table below for patents covering POTASSIUM PHOSPHATES around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2020081118 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for POTASSIUM PHOSPHATES

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1499331 SPC/GB13/034 United Kingdom ⤷  Sign Up PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
3141251 301099 Netherlands ⤷  Sign Up PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
1441735 08C0026 France ⤷  Sign Up PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
1718641 SPC/GB12/028 United Kingdom ⤷  Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
1499331 13C0055 France ⤷  Sign Up PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.